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INTRODUCTION  
Raloxifene hydrochloride 
1
 (Figure 1) belongs to the 
benzothiophene class of compound and it is currently used 
for prevention of osteoporosis in postmenopausal women. 
It was approved by Food and Drug Administration (FDA) 
in 1997. Chemically it is 6-Hydroxy-2- (4-hydroxy phenyl) 
benzo {b} thien-3-y l] [4-{2-(1-piperid inyl)-ethoxy}-
phenyl] methanone with a molecular weight 510.05 g/mol. 
It binds to the nuclear estrogen receptors (ERα and ERß) 
and either activates or blocks ER-induced gene 
transmission, depending on the tissue involved. Raloxifene 
hydrochloride demonstrates estrogen agonist effects on 
bone and blood lipid levels while it is a competitive 
antagonist of estrogen at mammary and uterine estrogen 
receptors 
2-3
. Raloxifene hydrochloride is cardio protective, 
in part due to its effects on plasma lipid d istribution. Like 
estradiol, raloxifene hydrochloride reduces total and low-
density lipoprotein (LDL) levels in p lasma. However, 
unlike estradiol, it does not increase plasma high-density 
lipoprotein (HDL) and triglyceride levels in plasma 
4
. 
There are also some adverse effects, namely increased 
incidences of hot flushes and in low percentage venous 
thromboembolic events 
5
. 
 
Figure 1: Chemical Structure of Raloxifene Hydrochloride 
Analytical methods described in literature for the 
determination of Raloxifene hydrochloride in biological 
and other matrices involve spect rophotometry 
6-13
, liquid  
chromatography 
14-30
, cap illary  elect rophores is  
31
 and 
resonance ray leigh  scattering 
32
.  
Quality control of pharmaceutical products requires 
identification and quantification of the active ingredient 
and its impurities for safety and efficacy reasons . 
Impurit ies and potential degradation products that may 
exist in medicines can change the chemical, 
pharmacological and toxico logical properties of the 
product. Since pharmacopoeias do not describe a suitable 
method for the determination of Raloxifene hydrochloride 
in pharmaceutical formulations, in the present work we 
developed simple, rap id and accurate reverse phase liquid 
chromatographic method for the determination of 
Raloxifene hydrochloride in tablets.  
MATERIALS AND METHODS 
Chemicals and Reagents  
Raloxifene Hydrochloride standard (purity 99.80%) was 
obtained from M/S BAL Pharma, India.  Methanol (HPLC 
grade), sodium acetate , glacial acetic acid , sodium 
hydroxide (NaOH), hydrochloric acid (HCl) and hydrogen 
peroxide (H2O2) were obtained from Merck , Ind ia. HPLC 
grade water was obtained from Merck, India. The drug 
products of Raloxifene Hydrochloride, i.e. RALISTA
®
 
(Cipla Ltd. India), FIONA
®
 (Dr. Reddy’s  Laboratories 
Ltd. India), RALOCIUM
®
  (Bal Pharma Ltd., India) 
available as tablets (Label claim 60.0 mg) were procured 
from the pharmacy store and all other chemicals were of 
an analytical grade and used as received.   
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Instrumentation      
Chromatographic separation was achieved by using a 
Shimadzu Model CBM-20A/20 Alite HPLC system, 
equipped with SPD M20A prominence photodiode array 
detector (250 mm × 4.6 mm, 5 µm particle size) 
maintained at 25 ºC.  
Chromatographic Conditions  
Isocratic elution was performed using sodium acetate: 
methanol (40:60, V/V) as mobile phase with a flow rate of 
1 mL/min. UV detection was performed at 287 nm. 
Preparation of Raloxifene hydrochloride Stock 
Solution 
Raloxifene hydrochloride stock solution (1000 μg/mL) was 
prepared by accurately weighing 25 mg of Raloxifene 
hydrochloride in a 25 mL amber volumetric flask and 
making up to volume with methanol. Working solutions 
for HPLC in jections were prepared on a daily basis from 
the stock solution in a solvent mixture of sodium acetate: 
methanol (40:60, V/V) (mobile phase). Solutions were 
filtered through a 0.45 μm membrane filter prior to 
injection and 20 µL was in jected into the HPLC system.  
Preparation of Sample Solutions   
Twenty tablets from each brand (RALISTA
® 
and 
RALOCIUM
®
) were procured, weighed and crushed to a 
fine powder. Powder equivalent to 25 mg Raloxifene 
hydrochloride was accurately weighed into a 25 ml 
volumetric flask and made up to volume with mobile 
phase. The contents of the volumetric flask were sonicated 
for 30 min to enable complete dissolution of Raloxifene 
hydrochloride. The solution was filtered and the filtrate 
was diluted with mobile phase. 20 μL of these solutions 
were injected into the system and the peak area was 
recorded from the respective chromatogram.  
Forced Degradation Studies/Specificity  
The study was intended to ensure the effective separation 
of Raloxifene hydrochloride and its degradation peaks of 
formulat ion ingredients at the retention time of Raloxifene 
hydrochloride. Separate portions of drug product and 
ingredients were exposed to the following stress conditions 
to induce degradation. Forced degradation studies were 
performed to evaluate the stability indicat ing properties 
and specificity of the method 
33
. All solutions for use in 
stress studies were prepared at an initial concentration of 1 
mg/mL of Raloxifene hydrochloride and kept at room 
temperature for 30 min. A ll samples were then diluted in 
mobile phase to give a final concentration of 50 μg/mL and 
filtered before inject ion.  
Acidic and Alkaline Degradation  
Raloxifene hydrochloride drug solution (1.0 mg/mL) was 
treated with 0.1 M HCl and kept at room temperature for 
30 min and then the stressed sample was neutralized and 
diluted with mobile phase to give a final concentration of 
50 μg/mL and filtered before injection.  
Similarly stress studies in alkaline conditions were 
conducted by exposing the drug sample solution with 0.1 
M NaOH for 30 min at room temperature and then the 
stressed sample was neutralized and diluted with mobile 
phase to give a final concentration of 50 μg/mL and 
filtered before inject ion.  
Oxidative Degradation  
Solutions for oxidative stress studies were conducted by 
treating the drug solution with 3% H2O2 for 30 min at  
room temperature and then diluted with mobile phase to 
give a final concentration of 50 μg/mL. 
Photolytic Degradation 
The drug solution (1 mg/mL) for photo stability testing 
was exposed to UV light for 4 hours in a UV light chamber 
(365 nm) and diluted with the mobile phase to give a final 
concentration of 50 μg/mL and filtered before inject ion.  
Method Validation  
The method was validated for the following parameters: 
system suitability, linearity, limit of quantitation (LOQ), 
limit of detection (LOD), precision, accuracy, selectivity 
and robustness 
34
. 
Linearity  
Linearity test solutions for the assay method were prepared 
from a stock solution at different concentration levels of 
the analyte (1.0-250 µg/mL). 20 µL of each solution was 
injected in to the HPLC system and the peak area of the 
chromatogram obtained was noted. The solutions 
extracted from the marketed formulat ions were injected  
in to the HPLC system and the peak area of the 
chromatograms was noted. The analytical curve was 
evaluated on three different days. The peak area vs. 
concentration data was analyzed with least squares linear 
regression. The slope and y-intercept of the calibration 
curve was reported. 
Precision  
The intra-day precision of the assay method was evaluated 
by carrying out 9 independent assays of a test sample of 
Raloxifene hydrochloride at three concentration levels (10, 
50 and 100 µg/mL) (n=3) against a qualified reference 
standard. The %RSD of three obtained assay values at 
three different concentration levels was calculated. The 
interday precision study was performed on three different 
days i.e. day 1, day 2 and day 3 at three different 
concentration levels (10, 50 and 100 µg/mL) and each 
value is the average of three determinations (n=3). The % 
RSD of three obtained assay values on three different days 
was calculated.  
Accuracy  
The accuracy of the assay method was evaluated in 
triplicate at three concentration levels (80, 100 and 120%), 
and the percentage recoveries were calcu lated. Standard 
addition and recovery experiments were conducted to 
determine the accuracy of the method for the 
quantification of Raloxifene hydrochloride in the drug 
product. The study was carried out in triplicate at 18, 20 
and 22 µg/mL. The percentage recovery in each case was 
calculated.  
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Sensitivity/Limit of quanti fication (LOQ) and limit of 
detection (LOD)  
The limit of quantification (LOQ) and limit of detection 
(LOD) were based on the standard deviation of the 
response and the slope of the constructed calibration curve 
(n=3), as described in International Conference on 
Harmonizat ion guidelines Q2 (R1) 
34
. Sensitivity of the 
method was established with respect to limit of detection 
(LOD) and LOQ for Raloxifene hydrochloride. LOD and 
LOQ were established by slope method as mentioned 
below. 
LOD = 
3.3 × standard deviation of y-intercept 
Slope of the calibration curve  
 
LOQ= 
10 × standard deviation of y-intercept 
Slope of the calibration curve 
LOD and LOQ were experimentally verified by inject ing 
six replicate injections of each impurity at the 
concentration obtained from the above formula. 
Solution Stability and Mobile Phase Stability  
The solution stability of Raloxifene hydrochloride in the 
assay method was carried out by leaving both the sample 
and reference standard solutions in tightly capped 
volumetric flasks at room temperature for 48 h. The same 
sample solutions were assayed at 12 h intervals over the 
study period. The mobile phase stability was also assessed 
by assaying the freshly prepared sample solutions against 
freshly prepared reference standard solutions at 12 h 
intervals up to 48 h. The prepared mobile phase remained 
constant during the study period. The % RSD of the 
Raloxifene hydrochloride assay was calculated for the 
mobile phase and solution stability experiments. An 
additional study was carried out using the stock solution by 
storing it in a t ightly capped volumetric flask at 4 ºC.  
RES ULTS AND DISCUSS ION  
The present proposed method is simple, precise, accurate 
and is applicable for a wide linearity range in comparison 
to the reported methods in the literature. A reversed-phase 
chromatographic technique was developed to quantitate 
Raloxifene hydrochloride at 287 nm. Methanol was chosen 
as an organic modifier in the mobile phase. Satisfactory 
resolution was achieved with use of a mixture of sodium 
acetate: methanol (40:60, V/V) as mobile phase with a 
flow rate of 1 ml/min as demonstrated in Figure 2. C18 
column was adopted for the analysis because it provided a 
better separation of the analytes. The present method is a 
stability indicating RP-HPLC method which was not 
reported earlier. 
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Figure 2: Representative chromatogram of Raloxifene hydrochloride (100 μg/mL)  
The present stability-indicat ing method for the 
determination of Raloxifene hydrochloride in  
pharmaceutical formulat ions is specific because the drug 
peak was well separated even in the presence of 
degradation products. Overall, the data demonstrated that 
the excip ients and the degradation products did not 
interfere with the Raloxifene hydrochloride peak, 
indicating the selectivity of the method. The complete 
separation of the analytes was accomplished in less than 10 
min and the method can be successfully applicable to 
perform long-term and accelerated stability studies of 
Raloxifene hydrochloride fo rmulat ions. 
HPLC Method Development and Optimization  
Initially the stressed samples were analyzed using a mobile 
phase consisting of water: acetonitrile (60:40, v/v) at a 
flow rate of 1.0 mL/min. Under these conditions, the 
resolution and peak symmetry were not satisfactory, so the 
mobile phase was changed to sodium acetate: methanol 
(40:60, V/V) with a flow rate of 1 ml/min
 
under which 
peaks were well resolved with good symmetry and 
sharpness. Therefore, mobile phase containing sodium 
acetate: methanol (40:60, V/V) ml/min was chosen as the 
best chromatographic response for the entire study.  
Method Validation  
System Suitability  
The system suitability test was performed to ensure that 
the complete testing system was suitable for the intended 
application. The parameters measured were peak area, 
retention time, tailing factor, capacity factor and 
theoretical plates. In all measurements the peak area varied 
less than 2.0%, the average retention time was 5.1 ± 0.05 
minutes. The capacity factor was more than 2, theoretical 
plates were 9976 (more than 2000) and tailing factor was 
1.21 (less than 2) for the Raloxifene hydrochloride peak. 
The proposed method offers high sensitivity and 
Raloxifene hydrochloride can be detected accurately. In all 
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the cases, the Raloxifene hydrochloride peak was well 
separated from the degradation products.  
Linearity  
The calibration curve for Raloxifene hydrochloride was 
linear over the concentration range of 1.0–250 μg/mL. The 
linearity data was given in Tab le 1.  
Table 1: Linearity of Raloxifene hydrochloride  
S. No. Conc. (µg/mL) Mean peak area ± SD %RSD 
1 1 120607.3 ± 420.48 0.35 
2 2 210763 ± 724.12 0.34 
3 5 474532 ± 415.1 0.09 
4 10 914800 ± 4107.18 0.45 
5 20 1925154 ± 2000 0.1 
6 50 4710544 ± 2252.07 0.05 
7 100 9327404 ± 1239.79 0.01 
8 150 14355444 ± 16977.73 0.12 
9 200 19064698 ± 8899.48 0.05 
10 220 20851161 ± 44404.39 0.21 
11 250 24105638 ± 23100.65 0.1 
 
A calibration curve was drawn by taking the concentration 
on the x-axis and the corresponding peak are on the y-axis. 
The regression equation was found to be y = 95604 x - 
26215 with correlation coefficient 0.9999.  
 
Figure 3: Calibration Curve of Raloxifene hydrochloride  
Precision  
The precision of the method was determined by 
repeatability (Intra-day precision) and intermediate 
precision (Inter-day precision) of the Raloxifene 
hydrochloride standard solutions. Repeatability was 
calculated by assaying three samples of each at three 
different concentration levels (10, 50 and 100 µg/mL) on 
the same day. The inter-day precision was calculated by 
assaying three samples of each at three different 
concentration levels ((10, 50 and 100 µg/mL) on three 
different days. The % RSD range was obtained as 0.16-
0.54 and 0.17-0.53 for intra-day and inter-day precision 
studies respectively (Table 2). 
Table 2: Intra-day and inter-day precision studies of Raloxifene hydrochloride  
S No. Conc. 
(µg/mL) 
Intra-day precision Inter-day precision 
Mean* ± SD % RSD Mean* ± SD % RSD 
1 10 914689 ± 3496.7 0.38 917227.7 ± 3276.9 0.36 
2 50 4740823 ± 25518.5 0.54 4720829 ± 24989.4 0.53 
3 100 9344304 ± 15036.8 0.16 9329345 ± 15459.1 0.17 
*Mean of three replicates 
Because the stability of standard solutions can also affect 
the robustness of analytical methods, the stability of 
standard solutions of the drug substance used in this 
method was tested over a long period of time. One portion 
of a standard solution was kept at room temperature and 
the other portion was stored under refrigeration at 
approximately 4ºC and the content of these solutions was 
regularly compared with that of freshly prepared solutions. 
No change in drug concentrations were observed for 
solutions stored under refrigeration. But it is recommended 
that the sample and standard solutions be freshly prepared 
in amber co lored flasks to protect from light. 
Accuracy  
The method accuracy was proven by the recovery test. A 
known amount of Raloxifene hydrochloride standard (10 
μg/mL) was added to aliquots of samples solutions and 
then diluted to yield total concentrations as 18, 20 and 22 
μg/mL as described in Table 3. The assay was repeated 
over 3 consecutive days. The resultant % RSD was 0.27 
(<2.0 %) with a recovery 99.40-99.9 %. 
Table 3: Accuracy - recovery study of Raloxifene hydrochloride by standard-addition method 
Sample No. Spiked Conc. (µg/mL) *Measured Conc. (µg/mL) (% ) Recovery* (% ) RSD *  
1 18 17.9 99.4 
0.27 2 20 19.9 99.5 
3 22 21.98 99.9 
*Mean of three replicates 
Limit of Detection and Limit of Quantification 
The LOQ and LOD were determined based on the 10 and 
3.3 times the standard deviation of the response, 
respectively, divided by the slope of the calibration curve. 
The LOD and LOQ were found to be 0.267 μg/mL and 
0.813 μg/mL respectively.  
Selectivity/Specificity  
The specificity of the developed method was determined 
by injecting sample solutions (50 μg/mL) which were 
prepared by forcibly degrading under such stress 
conditions as heat, light, oxidative agent, acid and base 
under the proposed chromatographic conditions. The 
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stability indicating capability of the method was 
established from the separation of Raloxifene 
hydrochloride peak from the degraded samples derived 
from the software. The degradation of Raloxifene 
hydrochloride was found to be very similar for both the 
tablets and standard.  
Solution Stability and Mobile Phase Stability   
The %RSD of the assay of Raloxifene hydrochloride from 
the solution stability and mobile phase stability 
experiments was within 2%. The results of the solution and 
mobile phase stability experiments confirm that the sample 
solutions and mobile phase used during the assays were 
stable up to 48 h at room temperature and up to 3 months 
at 4ºC.  
Analysis of Commercial Formulations (Tablets) 
The proposed method was applied to the determination of 
Raloxifene hydrochloride  tablets RALISTA
®, 
FIONA
®
 
and RALOCIUM
®
  and the result of these assays yielded 
99.96- 100.04 % respectively  with RSD < 2.0 %. The 
result of the assay (Table 4) indicates that the method is 
selective for the assay of Raloxifene hydrochloride without 
interference from the excip ients used in these tablets .
Table 4: Analysis of Raloxifene hydrochloride commercial formulation (Tablets) 
S. No Formulation Labeled claim (mg) *Amount found   (mg) %  Label claim ± SD* 
1 RALISTA
®
 60 59.98 99.96 ± 0.05 
2 FIONA
®
 60 60.03 100.0±0.01 
3 RALOCIUM
®
 60 60.02 100.04±0.01 
*Mean of three replicates 
The typical chromatograms for Raloxifene hydrochloride obtained from the extracted marketed fo rmulations  were shown 
in Figure 4a and 4b. 
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Figure 4(a): Representative Chromatogram of Raloxifene Hydrochloride (100 μg/mL) (RALOCIUM® 60 mg) 
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Figure 4(b): Representative Chromatogram of Raloxifene Hydrochloride (100 μg/mL) (RALIS TA® 60 mg) 
Forced Degradation Studies  
Raloxifene hydrochloride standard and tablet powder was found to be quite stable under dry heat conditions. Typical 
chromatograms obtained following the assay of stress ed samples are shown in Figure 5a -5d.  
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Figure 5a: Typical Chromatogram of Raloxifene hydrochloride (50 μg/mL) on Acidic degradation  
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Figure 5a: Typical Chromatogram of Raloxifene hydrochloride (50 μg/mL) on Alkaline degradation  
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Figure 5c: Typical Chromatogram of Raloxifene hydrochloride (50 μg/ mL) on Oxidative degradation  
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Figure 5d: Typical Chromatogram of Raloxifene hydrochloride (50 μg/mL) on Photolytic degradation 
Table 5: Forced degradation studies of Raloxifene hydrochloride 
Stress Conditions %  Drug 
Recovered 
%  Drug 
Decomposed 
Standard Drug 100 - 
Acidic Hydrolysis 97.48 2.52 
Alkaline Hydrolysis 96.65 3.35 
Oxidative degradation 97.47 2.53 
Photolytic degradation 98.48 1.52 
*Mean of three replicates 
A very slight decomposition was seen on exposure of 
Raloxifene hydrochloride drug solution to acidic (2.52), 
alkaline (3.35) and oxidation (2.53). During the oxidative 
degradation one major degradant was observed at 2.734 
mins without interfering the elution of drug peak (5.015 
mins) and the percentage of drug decomposition was found 
to be 2.53 % indicat ing that the drug is highly resistant 
towards oxidation. Raloxifene hydrochloride has 
undergone photo degradation (1.52) very slightly i.e. less 
than 2.0 %. Table 5 summarizes the data of degradation 
studies. 
CONCLUS ION 
The proposed stability-indicat ing HPLC method was 
validated as per ICH guidelines  and applied for the 
determination of Raloxifene hydrochloride in  
pharmaceutical dosage forms. The method was found to be 
accurate, precise, robust and specific as the drug peak did  
not interfere with the ext ra peaks aroused during the forced 
degradation studies. At the same time the chromatographic 
elution step is undertaken in a short time (< 6 min). No  
interference from any components of pharmaceutical 
dosage form or degradation products and therefore the 
method can be successfully applied to perform long-term 
and accelerated stability studies of Raloxifene 
hydrochloride formulations. In conclusion, the h igh 
sensitivity, good selectivity, accuracy and reproducibility 
of the proposed method is suitable for quality control 
analysis of complex pharmaceutical preparation containing 
Raloxifene hydrochloride. The reduction of acetonitrile  
consumption is one of the best solutions to the current 
global acetonitrile shortage and will safeguard against 
future risk. 
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